Table 3.

Disease characteristics at baseline (n = 93) and followup during golimumab treatment.

Baseline3 Mos6 Mos12 Mos
BASMI0.6(0.2–1.0)0.4(0.2–0.8)0.4(0.2–0.8)0.4(0.2–0.8)
MASES2(0–4)0(0–2)*
≥ 1 swollen joint16(17)17(19)15(18)8(9)
CRP, mg/l4(2–11)3(1–5)3(1–4)3(1–4)*
ESR, mm/h10(5–24)4(2–10)5(2–9)5(2–9)*
BASDAI5.4(3.8–6.5)3.9(1.9–6.3)3.6(1.5–6.0)3.3(1.5–5.1)*
BASFI4.5(2.6–6.0)3.0(1.3–5.3)3.6(1.2–5.9)3.2(0.8–5.5)*
ASDAS3.1(2.4–4.1)1.9(1.2–3.0)2.2(1.2–2.9)1.9(1.1–2.6)*
BAS-G, NRS6.5(5.5–7.9)5.0(3.0–7.0)4.5(2.5–7.0)4.3(1.5–6.5)*
Pain, NRS5.8(3.5–7.1)3.0(1.0–6.0)3.0(1.0–6.0)2.5(0.5–5.0)*
Patient disease activity, NRS7(5–8)4(2–7)4(1–6)3(1–6)*
Physician disease activity, NRS6(4–7)2(1–4)2(1–3)2(1–3)*
ASQoL9(4–13)6(1–11)6(1–11)4(1–10)*
ASAS20 responders29(36)34(45)39(49)*
  • Values are reported as n (% of total), mean (± SD), or median (Q1–Q3).

  • * Significant change (p < 0.01) compared to baseline. ASDAS: Ankylosing Spondylitis Disease Activity Score; ASQoL: AS Quality of Life questionnaire; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath AS Functional Index; BAS-G: Bath AS Global score; BASMI: Bath AS Metrology Index; ESR: erythrocyte sedimentation rate; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; NRS: numerical rating scale; ASAS: Assessment of Spondyloarthritis international Society (guidelines).